Back
ESC Premium Access

Cardiovascular outcome trials in type 2 diabetes: lessons learned and questions to ask.

Session: Cardiovascular disease prevention with antihyperglycaemic and cholesterol lowering therapy in type 2 diabetes
Topic: Diabetes, dysglycaemia and metabolic syndrome
Speaker: Professor L. Ryden (Stockholm, SE)
Event: ESC Congress 2017

Congress Presentation

Add to my library

Like

About the speaker

Professor Lars Ryden

Karolinska Institute, Stockholm (Sweden)
38 presentations
1 follower

4 more presentations in this session

State of the Art: cardiovascular disease prevention with antihyperglycaemic and cholesterol lowering therapy in type 2 diabetes

Speaker: Professor D. De Zeeuw (Groningen, NL)

Access
Slides
Video
Like
Thumbnail

Risk of major cardiovascular events in patients with type 2 diabetes with and without prior cardiovascular events: results from the LEADER trial

Speaker: Professor N. Poulter (London, GB)

Access
Abstract
Slides
Video
Like
Thumbnail

SUSTAIN 6: a post-hoc analysis of the effect of semaglutide on cardiovascular outcomes over time in subjects with type 2 diabetes

Speaker: Doctor E. Jodar Gimeno (Pozuelo de Alarcon, ES)

Access
Abstract
Slides
Video
Like
Thumbnail

Impact of CETP inhibition with evacetrapib in patients with diabetes mellitus: results from ACCELERATE

Speaker: Doctor V. Menon (Cleveland, US)

Access
Abstract
Slides
Video
Like
Thumbnail

Access the full session

Cardiovascular disease prevention with antihyperglycaemic and cholesterol lowering therapy in type 2 diabetes

Speakers: Professor L. Ryden, Professor D. De Zeeuw, Professor N. Poulter, Doctor E. Jodar Gimeno, Doctor V. Menon
Access
Like
Thumbnail

About the event

Image

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources